At a time when the world of medical imaging is all about artificial intelligence, our aim is to bring it within your reach!
Our technology lets radiologists and clinicians focus on quality of care by building artificial intelligence systems into their workflow, all with a focus on clinical needs.
Our natively AI-powered clinical apps are built to the highest clinical standards.
Innovative, collaborative solutions fully integrated into any healthcare information system
20 years
of innovation
1,200 customers
worldwide
70 employees
committed to saving lives
170 scientific papers
and several technology patents
Intrasense news
Intrasense announces the CE marking of Liflow®’s new version enhanced by AI dedicated to the liver
16 December 2024
Intrasense (FR0011179886 - ALINS), medical imaging software solutions expert and developer of Myrian® et Liflow®, is proud to announce that the Lilfow® solution obtained the CE certification under MDR1, integrating a new AI algorithm for the detection of focal liver lesions developed in collaboration with Guerbet (trade name: DUOnco™ Liver). This new version is being […]
Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow®, innovative solution dedicated to oncology imaging
3 December 2024
Guerbet (FR0000032526 GBT) worldwide expert in contrast agents and medical imaging solutions, Intrasense (FR0011179886 - ALINS), expert in medical imaging software solutions and developer of Myrian® and Liflow®, Gustave Roussy, 1st cancerology centre in France and Europe and Angers University Hospital (« Partners ») announce they have received €5.9M in funding from Bpifrance’s “Innovation in […]
Intrasense announces the CE marking of Myrian 2.13, enriched by the new version of Guerbet’s prostate AI
20 November 2024
Intrasense (FR0011179886 - ALINS), medical imaging software expert and developer of Myrian® and Liflow®, is proud to announce that the Myrian® 2.13 platform has obtained the CE marking under MDR1, including a major new version of the prostate AI developed by Guerbet, Veolity® LungCAD AI developed by MeVis Medical Solutions AG and Icobrain™ AI developed […]
Intrasense announces its participation in RSNA 2024, the world's leading medical imaging congress
6 November 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces its participation in the RSNA 2024 international imaging congress. Intrasense will be showcasing its new Liflow® solution, as well as the innovations of the new version of Myrian®, on the stand of its partner Guerbet, symbolizing a collaboration […]
Liflow®, a solution dedicated to oncology imaging, wins the JFR 2024 Innovation Prize in the “Healthcare IT and AI” category
30 September 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and the developer of Myrian® and Liflow®, is proud to announce that its Liflow® solution has been awarded the Prix Innovation JFR (Journées Francophones de la Radiologie) 2024 in the “Healthcare IT and AI” category.
Intrasense announces its half-year results for 2024
25 September 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® et Liflow®, announces its consolidated IFRS half-year results for 2024.
Guerbet and Intrasense announce the CE marking of DUOnco™ Liver, an artificial intelligence algorithm designed to detect focal liver lesions
23 September 2024
Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announce the CE marking under MDR of the liver AI developed by Guerbet (trading name: DUOnco™ Liver).
Intrasense attends the « Journées Francophones de Radiologie » 2024
9 September 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and Myrian® and Liflow® developer, announces its attendance in Journées Francophones de Radiologie (JFR) 2024, where will be presented for the first time the new solution Liflow® as well as the innovations of the new version of Myrian®.
Alexandre Salvador appointed CEO of Intrasense to accelerate strategic repositioning on high value-added medical solutions integrating AI in radiology
27 August 2024
The Board of Directors of Intrasense (FR0011179886 - ALINS), metting on August, 28 2024 at 5:30 pm under the chairmanship of Mr. François NICOLAS, has decided to appoint Mr. Alexandre SALVADOR as Chief Executive Officer of Intrasense.
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow® (the "Company"), today announced its half-year revenue for 2024 IFRS consolidated at Group level.
Intrasense presents its AI innovations at the SIRM congress in Italy
10 June 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces its participation in SIRM, the congress organized by the Italian Society of Medical and Interventional Radiology, to be held from June 20 to 23 in Milan (Italy).
Intrasense announces CE certification of Liflow® to the new European regulation (MDR)
29 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, is proud to announce that the company has obtained CE certification under MDR (European Union Medical Device Regulation 2017/745), for the first version of its Liflow® solution.
Intrasense announces the appointment of Jérôme Thiebaud as Chief Business Officer
24 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the appointment of Jérôme Thiebaud as the Group's Chief Business Officer.
Presentation of annual results for 2023 and ambitions for 2024
22 April 2024
Intrasense presents its 2023 annual results.Discover in this webinar the progress of Intrasense's medical imaging solutions, its 2024 objectives and ambitions.
Liflow®: an innovative AI-enhanced solution to optimize oncology follow-up
16 April 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces the regulatory submission of its Liflow® 1.0 solution (registered trademark of the Myra project), an oncology platform dedicated to the analysis of diagnostic imaging and cancer follow-up.
Intrasense and Guerbet announce CE certification of Myrian 2.12, enhanced with Guerbet's prostate AI
8 April 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian®, and Guerbet (FR0000032526 GBT), world leader in medical imaging, are proud to announce that the Myrian® 2.12 platform has obtained CE certification under MDR, integrating prostate AI developed by Guerbet, the Veolity® LungCAD AI developed by MeVis Medical Solutions AG […]
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and the developer of Myrian® (the "Company"), today announced its annual 2023 IFRS consolidated financial results certified at Group level.
Intrasense presents its innovations at the European Congress of Radiology (ECR) 2024
26 February 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, announces its participation at the ECR from February 28 to March 3, in Vienna (Austria).
Intrasense announces the certification of Myrian® to the new European regulation (MDR)
21 February 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian®, is proud to announce that the company has obtained the new CE certification under MDR (European Union Medical Device Regulation 2017/745), authorizing the marketing of the latest version of its Myrian® solution.
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and developer of Myrian® (the "Company"), today announced its 2023 consolidated IFRS revenue (uncertified) at Group level.
